Torque develops cell therapies that anchor stimulatory cytokines, antibodies, and small molecules directly to immune cells to direct their activity and increase efficacy and durability in the tumor microenvironment without systemic exposure. Its Deep-Primed™ therapeutics are designed to activate only the T cells that are targeting the tumor by anchoring immunomodulators to the surface of the immune cell so they act locally. The company applies its platform across multiple immune cell therapeutic classes, including CAR T cells, TCR therapeutics, NK cells, and tumor-associated antigen (TAA)-specific T cells. Torque is led by CEO Bart Henderson, President and Founder Chairman Ulrik Nielsen, PhD, and co-founder Darrell Irvine, PhD. Financially, the company raised $25m in a Series A financing announced in November 2017. The investment was made by Flagship Pioneering.

Total raised

$25M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2017